Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

MPN Advances Day 2017 | Diagnosis, classification and treatment of systemic mastocytosis

Systemic mastocytosis, though a rare disease, is more common than clinicians may think and diagnosis of the condition can often be missed. In this insightful interview, Deepti Radia, MBBS, MRCPI, FRCPath, of Guy’s and St Thomas’ Hospital NHS Foundation Trust, London UK, details the latest updates in the field, such as the new WHO classification guidelines for diagnosis and classification. Dr Radia also discusses the treatment options for this condition, which often consists of symptomatic treatment, but in cases of aggressive systemic mastocytosis there are now targeted treatments available, such as midostaurin, BLU-285 and DCC-2618. This video was recorded at the Myeloproliferative Neoplasms Advances Day 2017, London, UK.